Compare Dow Jones Industrial Average ETF (DIA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Johnson & Johnson — how do they compare? Dow Jones Industrial Average ETF trades at $516.07 (market cap $45.20B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 13.7× Dow Jones Industrial Average ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Dow Jones Industrial Average ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 104 Days and Johnson & Johnson for 129 Days on average.
| DIA | JNJ | |
|---|---|---|
Market Cap | $45.20B | $618.09B |
Volume | 4,095,368 | 6,050,983 |
52-Week High | $542.79 | $278.43 |
52-Week Low | $451.37 | $186.00 |
Typical Hold Time | 104 Days | 129 Days |
Sector | — | Health |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA trades at $511.65 with minimal daily movement (+0.12%). Technical indicators show a bearish trend with selling pressure outweighing buying signals 13-4. The ETF maintains scheduled dividend distributions through 2026, with upcoming payments in September and October. Market breadth indicators suggest broader market weakness, though DIA's Dow Jones Industrial Average exposure provides blue-chip stability.
The ETF faces headwinds from technical bearishness and market volatility, but its diversified Dow exposure offers defensive characteristics. Key risks include Fed policy uncertainty and economic slowdown concerns. Dividend consistency provides income appeal, though valuation metrics remain unavailable for analysis.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
